Veronica Roberts (UK Head of Competition, Regulation and Trade), Peter Rowland (Of Counsel) and Ruth Allen (Knowledge Lawyer) share their insights into navigating competition law and FDI regulation in the pharmaceutical sector. Looking ahead to 2025, they highlight some key risks to be aware of and offer practical tips on pro-active steps that companies can take to address them. Topics discussed include the types of anti-competitive agreements that are likely to be in the regulatory spotlight, significant developments in respect of abuse of dominance, the growing risk of competition damages actions, the approach of the UK and EU regulators to so-called "killer acquisitions" and the sensitivities around foreign investment in the pharmaceutical sector.